The Company has continued to advance its business and execute on...

The Company has continued to advance its business and execute on the commercialization strategy for its lead product, EndoBarrier® Therapy, to treat type 2 diabetes and/or obesity as evidenced by a 264% increase in revenue in the Quarter over the same period last year.

Commenting on the results, Stuart A. Randle, president and chief executive officer, stated, “We
are delighted with our results in the fourth quarter of 2012. The strong revenue numbers reflect
the tremendous effort by our sales and marketing teams and the solid foundation we have
established over the last 18 months in key markets around the world.